US10336802B2 – July 2, 2019 – Acylated glucagon analogue

Please complete the required fields.




Inventors :

Ditte Riber; Jakob Lind Tolborg; Dieter Wolfgang Hamprecht; Leo Thomas

Owner :

BOEHRINGER INGELHEIM INTERNATIONAL GMBH, GERMANY ZEALAND PHARMA A/S, DENMARK ZEALAND PHARMA A/S, DENMARK

Application Number :

US15566338

Document Number :

US10336802B2

Priority Date :

April 16, 2015

Filing Date :

April 15, 2016

Date of Grant/ Publication :

July 2, 2019

Class :

A61K31 / 64; A61K38 / 22; A61K38 / 26; A61K38 / 28; A61K45 / 06; A61K31 / 135; A61K31 / 137; A61K31 / 155; A61K31 / 365; C07K14 / 605; A61K31 / 7048

Abstract

The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

Claim(s)

1. A compound having the formula: R 1 -H-Aib-QGTFTSDYSKYLDERAAKDFIEWLE-K([17-Carboxy-heptadecanoyl]-isoGlu-GSGSGG)-A-R 2 ??(SEQ ID NO: 1) wherein R 1 is H (hydrogen), C 1-4 alkyl, acetyl, formyl, benzoyl or trifluoroacetyl; and R 2 is OH or NH 2 ; or a pharmaceutically acceptable salt thereof.

Summary

No Comments

Leave a comment

Sorry, you must be logged in to post a comment. Login